Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Next Generation Drug Conjugates Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The next generation drug conjugates market size has observed rapid expansion in recent years. It is anticipated to grow from $2.47 billion in 2025 to $2.85 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.5%. The historical rise in the market can be linked to factors such as the limitations associated with conventional chemotherapy, advancements made in biologics research, an increase in cancer prevalence, the expansion of specialty pharma companies, and the clinical success observed with early drug conjugates.
The next generation drug conjugates market is anticipated to undergo significant growth in the coming years. It is projected to reach $5.1 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 15.7%. This growth during the forecast period can be attributed to the broader implementation of personalized medicine, an expanding array of oncology drug pipelines, advancements in linker and payload chemistry, increased research and development investments, and a rise in regulatory clearances. Key trends for the forecast period include the increasing uptake of targeted drug delivery systems, an intensified focus on precision oncology therapies, the development of sophisticated payload technologies, the growing clinical utilization of conjugated therapeutics, and a higher demand for safer, more effective medications.
Get A Free Sample Report With In-Depth Market Insights:
Next Generation Drug Conjugates Market Growth Catalysts And Demand Drivers
The increasing occurrence of cancer is projected to drive the expansion of the next-generation drug conjugates market in the future. Cancer encompasses a range of illnesses marked by the unregulated proliferation and spread of abnormal cells within the body. Factors contributing to the surge in cancer cases include an aging global population, various lifestyle choices, exposure to environmental elements, advancements in diagnostic methods, hereditary predispositions, and infectious agents. Next-generation drug conjugates aid in combating cancer by providing focused treatments directly to cancerous cells, thereby boosting the effectiveness of therapy while reducing harm to healthy tissues. As an illustration, in February 2025, Cancer Australia, an Australian government body, reported 4,641 new cases of pancreatic cancer in 2024, comprising 2,414 in males and 2,227 in females, which indicates a rise from 3,968 cases in 2023. Consequently, the growing prevalence of cancer is a key impetus for the next-generation drug conjugates market’s growth.
Next Generation Drug Conjugates Market Segment Trends And Revenue Contributors
The next generation drug conjugates market covered in this report is segmented –
1) By Next-Generation Drug Conjugates Type: Peptide Receptor Radionuclide Therapy, Ligand Mediated RNAI Conjugate, Ligand Conjugated Anti Sense Medicine, Peptide Drug Conjugate
2) By Targeting Ligand Type: Amino Sugar, Lipid, Peptide, Small Molecule, Virus-Like Particles
3) By Payload Type: Oligonucleotide, Radionuclide, Peptide, Small Molecule
4) By Therapy: Monotherapy, Combination Therapy
5) By Indication: Gastroenteropancreatic Neuroendocrine Tumors, Prostate Cancer, Leptomeningeal Carcinomatosis Caused By Breast Cancer Brain Metastases, Hereditary Transthyretin Amyloidosis, Atherosclerotic Cardiovascular Diseases, Severe Hypertriglyceridemia, Hereditary Angioedema, Acute Hepatic Porphyria, Other Indications
Subsegments:
1) By Peptide Receptor Radionuclide Therapy (PRRT): Somatostatin Analogues, Radiolabeled Peptides
2) By Ligand Mediated RNAi Conjugate: SiRNA Ligand Conjugates, ShRNA Ligand Conjugates
3) By Ligand Conjugated Anti-Sense Medicine: Oligonucleotide Ligand Conjugates, Antisense Oligonucleotide Ligand Conjugates
4) By Peptide Drug Conjugate: Cytotoxic Peptide Conjugates, Therapeutic Peptide Conjugates
Next Generation Drug Conjugates Market Trends Shaping Long-Term Demand
Leading firms within the next-generation drug conjugates market are embracing a strategy of forming strategic partnerships to bolster their research and development strengths, hasten the introduction of new products, and enlarge their foothold in the market. Such alliances involve companies utilizing each other’s distinct advantages and assets to attain shared benefits and successful outcomes. An illustration of this occurred in November 2023, when Prelude Therapeutics Incorporated, a precision oncology firm in the US at the clinical stage, formed a collaboration with AbCellera Biologics Inc., a biotechnology company from Canada, with the aim of creating novel precision antibody-drug conjugates (ADCs) for cancer treatment. This collaboration will focus on the identification, evolution, and market introduction of pioneering antibody-drug conjugates (ADCs), commencing with an initiative centered on a SMARCA degrader combined with a unique antibody. The goal of this approach is to extend the medicinal uses of Prelude’s small-molecule SMARCA2 selective degraders to a larger group of patients, particularly individuals suffering from cancers not associated with SMARCA4 mutations.
Next Generation Drug Conjugates Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the next generation drug conjugates market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis International AG, AstraZeneca PLC, Daiichi Sankyo Company Limited, Eisai Co Ltd., Bicycle Therapeutics plc, Zymeworks Inc., Genentech Inc., MacroGenics Inc., Abzena plc, Innate Pharma S.A., CytomX Therapeutics Inc., ImmunoGen Inc., Ascentage Pharma Group International, Mersana Therapeutics Inc., Antengene Corporation Limited, Nurix Therapeutics Inc., Tubulis GmbH
View The Full Next Generation Drug Conjugates Market Report:
Next Generation Drug Conjugates Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the next generation drug conjugates market in 2025. The regions covered in the next generation drug conjugates market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
